Our profession is appropriately energized by the remarkable pace of therapeutic advances across the spectrum of immune-mediated inflammatory diseases.Targeted therapies, coupled with advances in basic and clinical immunology and rapidly evolving insights into the brain-immune axis, have transformed what we can offer our patients. Yet there may be an unintended consequence of this success. With such an extraordinary therapeutic armamentarium available — and even more on the horizon — we can become overly focused on suppressing inflammation as the answer to every patient who fails to meet the